Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

ReNeuron Signs Agreement with Welsh Government to Lease Facility

Published: Wednesday, April 16, 2014
Last Updated: Wednesday, April 16, 2014
Bookmark and Share
Agreement to lease a new R&D, manufacturing and headquarters facility in South Wales.

ReNeuron Group has announced that it has signed an agreement with the Welsh Government to lease a landmark building at Pencoed Technology Park, near Cardiff, South Wales.

A key element of ReNeuron’s £33 million funding in 2013 was support from the Welsh Government and the Welsh Life Sciences Fund, allied to the relocation of the business to a new facility in South Wales. This move will bring together ReNeuron’s world-class research and development activities, GMP cell manufacture and allied corporate functions in one location, providing operational synergies as the Company’s therapeutic candidates move through clinical development to future market approval. The Company envisages the creation of up to 70 further jobs to be based at the site as cell manufacturing comes on-stream and builds over the next two years and beyond.

ReNeuron plans to commence the relocation of its operations to this site in April 2015, when the conversion of the existing building is expected to be complete. The ground floor of this facility will provide the Company with more than 25,000 square feet of research and development laboratories, GMP clean rooms designed for automated cell culture, and office accommodation, with scope to expand further if required in the future. When licensed for GMP cell manufacture, the facility will provide for ReNeuron’s late-stage clinical and initial commercial product requirements, from 2016 onwards.

The cost of converting and fitting out the building will be borne by the Welsh Government as part of the above-mentioned financial support package.

Edwina Hart MBE, Minister for Economy, Science and Transport in the Welsh Government, said: “I am delighted that plans are now well underway for ReNeuron’s relocation to Wales. Life sciences is one of our priority economic sectors and regenerative medicine is fast becoming an emerging sub-sector for Wales thanks to the presence of some world-class researchers. We have ambitious plans to grow this sector and build on our existing strengths. Attracting a company of the calibre of ReNeuron is central to this strategy. Their pioneering work is renowned internationally and the decision to move to Wales has created interest around the world.”

Michael Hunt, Chief Executive Officer of ReNeuron, said: “We are delighted to have signed an agreement to lease this landmark building in South Wales, which marks a further significant step in ReNeuron’s business development strategy. When complete, we believe the building will house the UK’s most advanced commercial cell therapy manufacturing facility and we are delighted to continue to work with the Welsh Government to bring this important project to fruition. Taking full control of the manufacture of our cell-based therapies is a key value driver for our business, reducing risk and enabling considerable future cost savings through manufacturing efficiencies and downstream economies of scale. Combined with the recent success we have achieved in developing off-the-shelf cryopreserved cell therapy candidates, we believe we are at the forefront in creating a commercially viable cell therapy business.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Approves Start of Phase I/II Clinical Trial in the US
Company has received regulatory approval in the US with its hRPC therapy candidate for retinitis pigmentosa.
Tuesday, May 05, 2015
ReNeuron Provides Corporate Update
The Company believes reconfiguring the Board and expanding the executive leadership will take them through to full commercialisation.
Wednesday, April 23, 2014
ReNeuron Comments on EU Legal Opinion on Patenting of Human Embryonic Stem Cells
A legal opinion has been given by the advocate-general of the ECJ regarding a patent test case originally brought in Germany and ultimately referred to the ECJ.
Tuesday, May 03, 2011
A Progress Update on ReN009 Stem Cell Therapy for Peripheral Arterial Disease
The Reneuron Group have provided an update on the progress of its ReN009 stem cell therapy for peripheral arterial disease.
Wednesday, November 17, 2010
ReNeuron Receives Final Regulatory Approval to Commence Landmark Stroke Clinical Trial in UK
The approval represents the final national regulatory step in taking the ReN001 therapy into patients in the UK.
Monday, February 15, 2010
ReNeuron Signs Manufacturing Contract to Provide Stem Cells for Stroke Clinical Trial
ReNeuron Group announced that it has signed a contract with Angel Biotechnology Holdings, under which Angel will manufacture clinical-grade ReN001 stem cell lots for ReNeuron's Phase I clinical trial with its ReN001 therapy in disabled stroke patients.
Tuesday, June 09, 2009
ReNeuron Announces Filing IND Application to the FDA for ReN001
ReNeuron files IND application to commence human clinical studies with ReN001 stem cell therapy for stroke.
Friday, December 08, 2006
ReNeuron Demonstrates Key Characteristics with its Hepatocyte Cell Lines
These cell lines have been shown to express a range of adult human liver functional markers.
Monday, October 31, 2005
Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos